MedTrace Logo

Paraclinical Cardiometabolic Risk Assessment in Type 2 Diabetes

NCT07362953 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2188

Last updated 2026-01-23

No results posted yet for this study

Summary

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by impaired insulin action and increased cardiometabolic risk. Visceral adiposity, insulin resistance, systemic inflammation, and dyslipidemia play key roles in the development of cardiovascular disease in individuals with T2DM. In this context, simple, rapid, and cost-effective biomarkers are increasingly important for risk assessment. The triglyceride-glucose (TyG) index is a practical indicator of insulin resistance, while the Atherogenic Plasma Index (API) reflects cardiovascular risk related to dyslipidemia. The Systemic Immune Inflammation Index (SII), derived from routine blood counts, serves as a marker of systemic inflammation. This study aims to evaluate the predictive value of TyG, API, and SII in assessing insulin resistance, cardiometabolic risk, and inflammation in patients with T2DM, thereby supporting early diagnosis and improved clinical management.

Conditions

  • Dyslipidemia Associated With Type II Diabetes Mellitus

Sponsors & Collaborators

  • Tokat Gaziosmanpasa University

    lead OTHER

Principal Investigators

  • Elif A Delibaş · Tokat Gaziosmanpaşa Üniversitesi

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2025-11-15
Completion
2025-12-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07362953 on ClinicalTrials.gov